Abstract:To assess and compare the toxicity and efficacy between conventional fractionation and hypofractionated schedules in patients with painful bone metastases from primary liver cancer, and to explore the indications for the different fractionation schedules. We did a prospective, randomized, controlled trial which was registered as ChiCTR-TRC-10000967 (Chinese Clinical Trial Register) in our department. Between January 2009 and December 2014, 200 patients were enrolled and randomly assigned (1:1) to receive either 2 Gy per fraction with 20 fractions for bone metastases without expansile soft-tissue masses and 30 fractions for bone metastases with expansile soft-tissue masses (A group), or 4 Gy per fraction with 7 fractions for bone metastases without expansile soft-tissue masses and 10 fractions for bone metastases with expansile soft-tissue masses (B group) by a central computer-generated allocation sequence using dynamic minimization to conceal assignment. All pain scores were recorded according to the Numerical rating scale. Mean follow-up for all patients was 9.3 months. The overall response rate and complete response rate in the A group (96.0% and 41.0%) seem higher than those in the B group (92.0% and 37.0%), but do not have significant differences (P = 0.499). The fractions for the response to radiotherapy leading to pain relief were significantly more in the A group (6f) than in the B group (4f), P < 0.001. The median durations of overall pain relief for the A group were 5.0 and 4.2 months in the B group. Grade I and II acute upper gastrointestinal toxicity were 13.0% and 3% in the A group and of 19.0% and 8.0% in the B group. One patient in the B group was observed in Grade III acute upper gastrointestinal toxicity. These differences were not statistically significant. Mild acute lower gastrointestinal toxicities were recorded in both groups. Grade I and II acute lower gastrointestinal toxicity were 11.0% and 3% in the A group and of 18.0% and 5.0% in the B group. More fatigue was recorded in the B group (39.0%) than that in the A group (26.0%). The median overall survival for all patients was 7.2 months (95% CI, 5.60–8.80). No significant differences were observed in the overall survival between the A group with 7.4 months (95% CI, 5.94–8.86) and the B group with 6.7 months (95% CI, 3.99–9.81). On multivariate analyses, survival was significantly associated with well-controlled intrahepatic tumor, Karnofsky performance status (KPS), γ-glutamyltranspeptidase levels, α-fetoprotein levels, and the treatment of Zoledronic acid, Child-Pugh classification, and the complete response to treatment. The time of the response to radiation therapy leading to pain relief was appeared later in the conventional fractionation schedule than the hypofractionated schedule, but the median duration of overall pain relief in the conventional fractionation schedule was longer.

[Efficacy of hypofractionated radiotherapy combined with docetaxel for treatment of bone metastasis of lung cancer].

Treatment Toxicity and Efficacy in Comparison Conventional Fractionation with Hypofractionation for Bone Metastases from Primary Liver Cancer

Efficacy analysis of zoledronic acid combined with radiotherapy and combined with chemotherapy for bone metastasis of non-small cell lung cancer

Radiotherapeutic Management and Prognostic Factors for Patients with Bone Metastases of Postoperative Breast Cancer

Prognostic Factors and Effect of Radiotherapy for Patients with Bone Metastasis from Primary Liver Cancer

Combined chemotherapy of zoledronic acid and pamidronate in the treatment of bone metastases from nonsmall cell lung cancer and the effects on pain stress and bone metabolic indices

Clinical Comparative Study of Zoledronic Acid Versus Pamidronate Disodium in the Treatment of Pain of Skeletal Metastases Lung Cancer

WITHDRAWN: A Randomized Trial of Conventional Fraction Versus Hypofraction Radiotherapy for Bone Metastases from Hepatocellular Carcinoma

Bone cementoplasty accompanied by radiotherapy for malignant tumor patients with bone metastaese: To be the first choice?

Analysis of Therapeutic Effect of Bonin Combined with Chemotherapyin Bone Metastases of Advanced Lung Cancer

A Clinical Study of Different Administration of Pamidronate in the Patients with Painful Bone Metastases Due to Lung Cancer

Efficacy of 8 Gy Single Fraction Palliative Radiation Therapy in Painful Bone Metastases: A Single Institution Experience

Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia to cure advanced ovarian cancer

Efficacy of Medroxyprogesterone Acetate Combined with Ondansetron on Preventing Vomiting Induced by Chemtherapy for Non-Small Cell Lung Cancer

Efficacy of chemotherapy combined with pamidronate disodium in treatment of cancer bone metastasis

Different Radiotherapy Fractionation Schedules Compared Clinically and Radiographically

Local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: An observational retrospective cohort study

Palliative pain relief and safety of percutaneous radiofrequency ablation combined with cement injection for bone metastasis

A application of radiofrequency ablation in the palliative treatment of bone metastases

Effect of the Standardized Management of Cancer Pain on Patients with Bone Metastasis of Lung Cancer in China

Clinical efficacy and safety of bone cement combined with radiofrequency ablation in the treatment of spinal metastases